William Blair Analysts Boost Earnings Estimates for Repligen

Repligen Co. (NASDAQ:RGEN - Free Report) - Equities researchers at William Blair upped their FY2025 earnings per share estimates for shares of Repligen in a research note issued to investors on Wednesday, April 30th. William Blair analyst M. Larew now expects that the biotechnology company will post earnings of $1.68 per share for the year, up from their previous estimate of $1.67. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen's Q3 2026 earnings at $0.58 EPS and FY2026 earnings at $2.28 EPS.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Repligen's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.28 EPS.

Several other research firms have also weighed in on RGEN. HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Repligen in a research note on Monday. Royal Bank of Canada decreased their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Monday, April 28th. TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective for the company. Finally, Canaccord Genuity Group lowered their target price on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research note on Wednesday, April 16th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $173.25.

Repligen Stock Down 2.8 %

Shares of NASDAQ:RGEN traded down $3.67 during midday trading on Friday, hitting $126.74. The stock had a trading volume of 720,069 shares, compared to its average volume of 720,732. The company has a market cap of $7.12 billion, a P/E ratio of -248.71, a PEG ratio of 4.54 and a beta of 1.21. Repligen has a 12 month low of $102.97 and a 12 month high of $182.52. The business's 50-day simple moving average is $136.86 and its 200-day simple moving average is $145.74. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Insider Activity

In related news, Director Margaret Pax purchased 250 shares of the stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Repligen

Several hedge funds have recently added to or reduced their stakes in the business. Ballentine Partners LLC grew its holdings in Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after acquiring an additional 72 shares during the period. CIBC Asset Management Inc lifted its holdings in Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after purchasing an additional 81 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 90 shares during the period. Louisiana State Employees Retirement System lifted its stake in shares of Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock valued at $2,087,000 after buying an additional 100 shares in the last quarter. Finally, Utah Retirement Systems boosted its stake in Repligen by 1.1% in the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after purchasing an additional 100 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.